首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Lancet Haematology

Lancet Haematology杂志,由Lancet Publishing Group出版,于2014年创刊,12 issues/year,出版语言English,ISSN:2352-3026。

投稿咨询
Lancet Haematology
Lancet Haematology
Lancet Haematology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
20.4
CiteScore
29.4
期刊收录
SCI、SCIE

Lancet Haematology(中文译名:《柳叶刀血液学》),ISSN:2352-3026,是Lancet Publishing Group出版的国际性学术期刊,创刊于2014年,以12 issues/year形式稳定发行,2026年总发文量约69篇。该刊采用非OA开放访问,学科归属为HEMATOLOGY。该刊是医学、血液学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达20.4,2025年期刊CiteScore为29.4,2025年期刊自引率约2%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Lancet Haematology长期聚焦医学、血液学及相关产业的技术应用前沿,在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、血液学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Italy、France、Netherlands、GERMANY (FED REP GER)、Spain等为核心发文国家与地区;ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)UNIVERSITY OF LONDON、UNIVERSITY OF TEXAS SYSTEM、HARVARD UNIVERSITY、UNIVERSITE DE PARIS、DANA-FARBER CANCER INSTITUTE、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
1区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 3 / 103

97.6

学科:HEMATOLOGY SCIE Q1 2 / 103

98.54

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 4 / 97

96.4

学科:HEMATOLOGY SCIE Q1 3 / 97

97.42


中国学者近期发文

1
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VT

Author:Cheng, Zhang; Jin, Yiqi

Journal: LANCET HAEMATOLOGY. 2026; Vol. 13, Issue 3, pp. e124-e124. DOI:

2
Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 tria

Author:Wang, Xin-Yue; Zhang, Xi-Mei; Wang, Liang; Gao, Lin-Rui; Chen, Ke; Feng, Xiao-Li; Rao, Wei; Zheng, Rong; Wu, Yun-Peng; Song, Yong-Wen; Fang, Hui; Chen, Bo; Jin, Jing; Liu, Yue-Ping; Jing, Hao; Tang, Yuan; Zhang, Wen-Wen; Zhai, Yi-Rui; Lu, Ning-Ning; Li, Ning; Xia, Chang-Fa; Wang, Shu-Lian; Liu, Xin; Li, Ye-Xiong; Qi, Shu-Nan

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e442-e450. DOI: 10.1016/S2352-3026(25)00071-7

3
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitor

Author:Risitano, Antonio M.; Kulasekararaj, Austin G.; Scheinberg, Phillip; Roeth, Alexander; Han, Bing; Maciejewski, Jaroslaw P.; Ueda, Yasutaka; de Castro, Carlos M.; Di Bona, Eros; Fu, Rong; Zhang, Li; Griffin, Morag; Langemeijer, Saskia M. C.; Panse, Jens; Schrezenmeier, Hubert; Barcellini, Wilma; Mauad, Vitor A. Q.; Schafhausen, Philippe; Tavitian, Suzanne; Beggiato, Eloise; Chew, Lee Ping; Gaya, Anna; Huang, Wei-Han; Hojang, Jun; Kitawaki, Toshio; Kutlar, Abdullah; Notaro, Rosario; Pullarkat, Vinod; Schubert, Joerg; Terriou, Louis; Uchiyama, Michihiro; Lee, Lily Wong Lee; Yap, Eng-Soo; Frieri, Camilla; Marano, Luana; de Fontbrune, Flore Sicre; Gandhi, Shreyans; Trikha, Roochi; Alashkar, Ferras; Yang, Chen; Liu, Hui; Kelly, Richard J.; Hoechsmann, Britta; Lawniczek, Tomasz; Mahajan, Navin; Solar-Yohay, Susan; Kerloeguen, Cecile; Ferber, Philippe; Kumar, Rakesh; Wang, Zhixin; Thorburn, Christine; Maitra, Samopriyo; Li, Shujie; Verles, Aurelie; Dahlke, Marion; de Latour, Regis Peffault

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e414-e430. DOI:

4
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancie

Author:Broeckelmann, Paul J.; Cliff, Edward R. Scheffer; Iacoboni, Gloria; Simon, Florian; Horowitz, Mary M.; Keating, Armand; Mateos, Maria-Victoria; Mohty, Mohamad; Sidana, Surbhi; Song, Yuqin; Wingard, John R.; Thanarajasingam, Gita

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e470-e481. DOI: 10.1016/S2352-3026(25)00051-1

5
Anti-GPRC5D CART-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CART-cell therapy: a single-centre, single-arm, phase 2 tria

Author:Xia, Jieyun; Sun, Qian; Zhou, Dian; Li, Hujun; Wang, Ying; Qi, Yuekun; Cao, Jiang; Yan, Zhiling; Li, Depeng; Cheng, Hai; Sang, Wei; Zhu, Feng; Sun, Haiying; Chen, Wei; Qi, Kunming; Yan, Dongmei; Qiu, Tingting; Hu, Tingyu; Gu, Weiying; Qian, Jun; Xia, Fan; Qi, Na; Jin, Congqian; Liu, Yang; Wang, Xue; Zhang, Yanlei; Peng, Shuixiu; Li, Zhenyu; Chang, Alex H.; Xu, Kailin

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 5, pp. e365-e375. DOI: 10.1016/S2352-3026(25)00048-1

6
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 stud

Author:Zhao, Xin; Sun, Jing; Zhang, Zhihua; Chen, Miao; Gong, Tiejun; He, Guangsheng; Li, Yingmei; Liu, Hong; Li, Fei; Li, Xin; Zhou, Hu; Wang, Xiaoqin; Hong, Mei; Lei, Lei; Yin, Hongyan; Luo, Xian; Li, Yang; Fan, Songhua; Guo, Xiaojun; Shi, Michael M.; Su, Weiguo; Zhang, Liansheng; Han, Bing; Zhang, Fengkui

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 2, pp. e97-e108. DOI: 10.1016/S2352-3026(24)00344-2

7
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre single-arm, phase 2 tria

Author:Alderuccio, Juan Pablo; Alencar, Alvaro J.; Schatz, Jonathan H.; Kuker, Russ A.; Pongas, Georgios; Reis, Isildinha M.; Lekakis, Lazaros J.; Spiegel, Jay Y.; Sandoval-Sus, Jose; Beitinjaneh, Amer; Stanchina, Michele D.; Trabolsi, Asaad; Lossos, Izidore S.; Rosenblatt, Joseph D.; Lessen, David S.; Moskowitz, Craig H.

Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 1, pp. e23-e34. DOI: 10.1016/S2352-3026(24)00345-4


在线咨询

Lancet Haematology

国际简称:LANCET HAEMATOL参考译名:柳叶刀血液学

年发文量:69 CiteScore:29.4 是否预警:否 Gold OA文章占比:11.88% 研究类文章占比:82.61%

杂志社联系方式:THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB

Lancet Haematology